Market intelligence, clinical progress, and high-purity reagents for KAT6A (MYST3) inhibitor and degrader development. Address critical selectivity challenges versus KAT6B and resistance mechanisms in AML and breast cancer therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KAT6A chromatin modifier drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Catalytic Enzyme / Antigen | KAT6A (MYST3) Full-Length & Catalytic Domain (aa 355-612). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. GST or His-tagged. | View KAT6A Products |
| Resistance Mutants | KAT6A Mutant Proteins (Acetyl-CoA pocket variants). Designed for resistance mechanism studies. Endotoxin controlled. | View KAT6A Products |
| Gene Delivery | KAT6A Promise-ORF / Lentivirus. Full-length ORF for stable overexpression. Titer >10^6 TU/ml. | View KAT6A Products |
| Benchmark Antibody | Anti-KAT6A Benchmark Antibody. Recombinant positive control for assay validation. | View KAT6A Products |
| Validation Tool | KAT6A siRNA Set. For knockdown specificity control and target validation. | View KAT6A Products |
| Selectivity Counter-Screen | KAT6B (MORF) Catalytic Domain. Critical homology target for selectivity assays. HEK293 expressed. | View KAT6B Products |
| Related Target A | ESR1 (Estrogen Receptor Alpha). Synergistic pathway co-target for ER+ breast cancer models. | View ESR1 Products |
| Related Target B | BRD9 Recombinant Protein. GBAF chromatin remodeling complex partner for PPI assays. | View BRD9 Products |
| Related Target C | ENL (YEATS Domain) Recombinant Protein. Histone acetylation reader interacting with KAT6A substrates. | View ENL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| KAT6A vs KAT6B Selectivity Screening | Matched human KAT6A & KAT6B catalytic domains with >95% purity, distinct tags for simultaneous multiplex assays. |
| Resistance Mutation Mechanism Studies | Site-specific mutant panel targeting acetyl-CoA binding pocket; sequence-verified. |
| Cellular Target Engagement (CETSA) | Lentivirus particles for stable KAT6A-overexpressing cell lines; native folding confirmation. |
| Functional Rescue Experiments | siRNA-resistant ORF variants available for rescue assay specificity confirmation. |
| Enzymatic Assay Reproducibility | High Purity (>95%), Endotoxin Controlled recombinant catalytic domains. |
| Lack of Controls / False Positives | Clinical Benchmark Antibodies and validated siRNA included for robust assay validation. |
Live KAT6A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The KAT6A inhibitor landscape is undergoing strategic recalibration following Pfizer's discontinuation of PF-07248144 in solid tumors due to hepatic safety and efficacy boundaries. The field is pivoting toward acute myeloid leukemia (AML) differentiation strategies and next-generation modalities. As first-generation catalytic inhibitors face selectivity challenges against the highly homologous KAT6B paralog, the next wave of R&D focuses on covalent inhibitors, PROTAC degraders, and rationally designed combination therapies with BCL-2 or MEK inhibitors to overcome emerging drug resistance. Major players include City of Hope (CTX-712) in AML, Biomea Fusion (BMF-500) with covalent targeting, and emerging biotechs exploring PROTACs for refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Reversible Small Molecule | Pfizer, Senhwa Biosciences, City of Hope (CTX-712) | ER+ Breast Cancer, AML | Enzymatic HAT activity assay; KAT6B selectivity panel (>95% purity proteins). |
| Covalent Inhibitor | Biomea Fusion (BMF-500) | Solid Tumors, AML | Irreversible binding kinetics; Cys-targeting mutant proteins. |
| PROTAC Degrader | Emerging Biotech, EpiMetheus Biosciences | Hematologic Malignancies, Refractory Solid Tumors | Ternary complex formation (KAT6A-PROTAC-E3 ligase); cellular knockdown validation. |
Future Outlook & Assay Strategy
Beyond clinical pipelines, the next 3-5 years will see increased demand for standardized resistance mutant proteins, CETSA assays for target engagement, and PPI reagents (BRD9, ENL) for functional complex studies. Combination therapies with CDK4/6 inhibitors and endocrine therapy in ER+ breast cancer will dominate, while PROTAC technology is expected to reach IND stage by 2025-2026. TarMart's solution ecosystem—spanning wild-type and mutant proteins, lentivirus, antibodies, and siRNA—covers the full spectrum of assay needs from selectivity screening to mechanism validation.